Holen Sie sich die Stockscreener-App
3.47
9.81%
0.31
Handel nachbörslich:
3.48
0.010
+0.29%
Schlusskurs vom Vortag:
$3.16
Offen:
$3.15
24-Stunden-Volumen:
97,608
Relative Volume:
1.65
Marktkapitalisierung:
$32.55M
Einnahmen:
$2.57M
Nettoeinkommen (Verlust:
$-13.54M
KGV:
-0.621
EPS:
-5.5882
Netto-Cashflow:
$-23.50M
1W Leistung:
+13.77%
1M Leistung:
-11.48%
6M Leistung:
-47.74%
1J Leistung:
+0.00%
1-Tages-Spanne:
$3.06
$3.50
1-Wochen-Bereich:
$2.83
$3.50
52-Wochen-Spanne:
$2.75
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Firmenname
Tvardi Therapeutics Inc
Sektor
Branche
Telefon
(713) 489-8654
Adresse
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
3.47 | 29.65M | 2.57M | -13.54M | -23.50M | -5.5882 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-10-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-10-13 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | Eingeleitet | Raymond James | Outperform |
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Eingeleitet | BTIG Research | Buy |
| 2024-06-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Herabstufung | Needham | Buy → Hold |
| 2024-06-13 | Herabstufung | Stifel | Buy → Hold |
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
Alle ansehen
Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten
Pulmonary Fibrosis Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeut - Barchart
Published on: 2026-04-13 19:29:33 - baoquankhu1.vn
Weekly Trades: What hedge funds are buying Tvardi Therapeutics IncPortfolio Gains Summary & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
TVRD Options Volatility — NASDAQ:TVRD - TradingView — Track All Markets
Tvardi Therapeutics (TVRD) Price Target Decreased by 43.91% to 8.50 - MSN
Portfolio Shifts: What hedge funds are buying Tvardi Therapeutics IncTrade Entry Summary & Community Verified Swing Trade Signals - baoquankhu1.vn
Analysis Recap: Is Tvardi Therapeutics Inc attractive at current valuation2026 Highlights & Entry and Exit Point Strategies - baoquankhu1.vn
Tvardi Therapeutics (NASDAQ:TVRD) Cut to Sell at Wall Street Zen - Defense World
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium - Sahm
BTIG Research Reaffirms Buy Rating for Tvardi Therapeutics (NASDAQ:TVRD) - Defense World
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and Forte Biosciences (FBRX) - The Globe and Mail
Barclays Reaffirms Their Hold Rating on Tvardi Therapeutics (TVRD) - The Globe and Mail
Tvardi management heads to New York for Apr. 14 biotech symposium - Stock Titan
Barclays Lowers Price Target for Tvardi Therapeutics (TVRD) | TV - GuruFocus
Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development - TipRanks
Tvardi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView — Track All Markets
Tvardi Therapeutics (TVRD) Sees Price Target Cut by Piper Sandler | TVRD Stock News - GuruFocus
Piper Sandler cuts Tvardi Therapeutics price target on trial timing By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Neutral on Tvardi Therapeutics stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Neutral on Tvardi Therapeutics stock - Investing.com
Piper Sandler cuts Tvardi Therapeutics price target on trial timing - Investing.com
Tvardi Therapeutics (NASDAQ: TVRD) registers 2,084,117 resale shares; clinical updates - Stock Titan
Tvardi Therapeutics (NASDAQ: TVRD) adds auditor consent in S-1 amendment - Stock Titan
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update - Bitget
Tvardi: Q4 Earnings Snapshot - Barchart.com
Tvardi Therapeutics (NASDAQ: TVRD) outlines STAT3 trial plans - Stock Titan
Tvardi (NASDAQ: TVRD) narrows 2025 loss and eyes key 2026 trial data - Stock Titan
Tvardi Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Tvardi Therapeutics Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Published on: 2026-03-31 03:05:34 - baoquankhu1.vn
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Consensus Price Target from Analysts - Defense World
Performance Recap: Will Tvardi Therapeutics Inc outperform during market rallies - baoquankhu1.vn
Tvardi Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | TVRD | US1407553072 - marketscreener.com
Tvardi Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | 69C | US1407553072 - marketscreener.com
Stop Loss: Is Tvardi Therapeutics Inc part of any major index2026 Short Interest & High Yield Equity Trading Tips - baoquankhu1.vn
Aug Swings: What hedge funds are buying Tvardi Therapeutics IncDollar Strength & Real-Time Sentiment Analysis - baoquankhu1.vn
Purchase/sale of business (net) of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
Published on: 2026-03-12 05:56:22 - baoquankhu1.vn
Tvardi Therapeutics (TVRD) Stock Analysis Report | Financials & Insights - Benzinga Japan
What sentiment indicators say about Tvardi Therapeutics Inc. stockPortfolio Update Report & Free Community Consensus Stock Picks - Naître et grandir
Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting - The Globe and Mail
Tvardi Therapeutics sets June 9, 2026 annual meeting; proxy and nomination deadlines announced - TradingView
[424B3] Tvardi Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Key deadlines for Tvardi Therapeutics (NASDAQ: TVRD) 2026 stockholder meeting - Stock Titan
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Average Price Target from Brokerages - Defense World
Why Did Tvardi Therapeutics Stock Plummet 87% Pre-Market Today? - Stocktwits
Growth Report: Is Tvardi Therapeutics Inc attractive for institutional investorsInsider Selling & Entry Point Confirmation Alerts - baoquankhu1.vn
Tvardi Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | 0HTC | US1407553072 - marketscreener.com
CARA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Free cash flow per share of Tvardi Therapeutics Inc. – FWB:69C - TradingView
Tvardi Therapeutics, Inc. (TVRD): Investor Outlook on the Biotech Company’s 125% Potential Upside - DirectorsTalk Interviews
Finanzdaten der Tvardi Therapeutics Inc-Aktie (TVRD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):